NCT06780007

Weight Loss Effect of Akkermansia Muciniphila in Obese Patients

Effect of Akkermansia Muciniphila Akk11 on Weight Loss in Obese Patients: a Multicenter, Randomized, Double-blind, Placebo-controlled Study.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 106 (actual)
• Sponsor: Wecare Probiotics Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study intends to study the effect of Akkermansia muciniphila on weight loss and the improvement of blood inflammation and metabolic indexes in obese patients with low Body Mass Index (BMI) through multi-center clinical studies, and for the first time to innovatively explore the weight loss mechanism of Akkermansia muciniphila by comparing the changes in brain function and fecal microbiota before and after intervention.

Conditions

• 28≤BMI≤35Kg/m2

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Probiotic	The trial phase of the study will last 12 weeks and each subject will make 4 follow-up visits (day 0, week 4, week 8 and week 12).
DIETARY_SUPPLEMENT	Placebo	The trial phase of the study will last 12 weeks and each subject will make 4 follow-up visits (day 0, week 4, week 8 and week 12).

Timeline

• Start date: 2025-01-21
• Primary completion: 2025-02-28
• Completion: 2025-06-16
• First posted: 2025-01-17
• Last updated: 2025-09-03

Locations

1 site across 1 country: China